Table 3

Adverse events, morbidity, and mortality at 1-month*

Event typeAll (n=167)DL (n=80)SL/SLS (n=87)p Value
Thromboembolic events24 (14.4%)15 (18.8%)9 (10.3%)0.130
  • Asymptomatic

11 (6.6%)9 (11.3%)2 (2.3%)0.027
  • Symptomatic without sequelae

8 (4.8%)4 (5.0%)4 (4.6%)1.000
  • Symptomatic with sequelae

5 (3.0%)2 (2.5%)3 (3.4%)1.000
Intraprocedural rupture2 (1.2%)1 (1.3%)1 (1.1%)1.000
Intracranial hemorrhage1 (0.6%)1 (1.3%)0 (0.0%)0.479
Morbidity†5 (3.0%)3 (3.8%)2 (2.3%)0.671
Mortality0 (0.0%)0 (0.0%)0 (0.0%)NA
  • *One patient withdrew his consent between the procedure and the 1-month follow-up.

  • †Modified Rankin Scale (mRS) score >2 if baseline ≤2. mRS +1 or more if baseline >2. mRS >2 and ruptured at baseline.